

BACKGROUND

Cancer centers receive multiple requests for information from sponsors and their contract research organizations (CROs) to assess a site's feasibility to conduct a clinical trial. This involves assessments in many areas:

- Site logistics
- Technical capabilities
- Accrual potential
- Activation timelines
- Administrative infrastructure
- Site-specific standard operating procedures

Gathering information in these areas requires lengthy questionnaires, access to portals, multiple email conversations, and meetings in addition to required pre-site selection visits (PSSVs). The requests for information and required questionnaires are extensive, time-consuming, and in many cases duplicative.

METHOD

- Our goal is to streamline communication during the site selection process to work more efficiently and collaboratively with our sponsors/CROs as well as ensure accuracy and consistency of information provided during the site selection process.
- By creating and maintaining a comprehensive document with site-specific information and answers to frequently asked questions for our sponsors/CROs, we expect to improve efficiencies for all parties by reducing the time it takes to confirm site selection.

Improving Efficiency and Time Management During the Site Selection Process: A Collaborative Approach

Leanne Lujan, BS, CCRP; Brett Johnson, BS, CCRC; Sally Fairbairn, BS, CCRP; Elizabeth Constantz, BS, CCRP; Janna Espinosa, BA, CCRP; Jessica Moehle, BS, CCRP; Theresa L. Werner, MD; Susan Sharry, BS, CCRP

Huntsman Cancer Institute at the University of Utah

RESULTS

We created a comprehensive new study start-up packet to give sponsors/CROs as soon as site selection discussions commence. The packet includes the following:

- Site-specific study start-up requirements
- Activation timelines
- Technical capabilities
- Answers to frequently asked questions

We provide this comprehensive document to our sponsors and CROs to help them assess the feasibility of conducting clinical research at HCI in a more efficient manner.

TABLE OF CONTENTS

Quick Facts about Huntsman Cancer Institute
Clinical Research Program Managers
Site Contact List
New Study Approval Process
Conflict of Interest Office and Office of Sponsored Projects
Contract and Budget FAQ.
IRB and Regulatory FAQ
Additional Regulatory Considerations
Investigational Pharmacy and Drug Dispensing FAQ
Specimen Processing, Local Lab, and Pathology FAQ
Radiology and Imaging FAQ
Imaging Review, Quantitative Assessment, and Reporting for Clinical Trials
Monitoring, Electronic Data Capture (EDC) and Medical Records FAQ
Infusion FAQ
Site Training FAQ
<u>Appendices:</u> Local Lab Normal Ranges, SOPs, AE Flowchart, IRB Guidance Documents;
Templates
Appendices: Local Lab Normal Ranges, SOPs, AE Flowchart, IRB Guidance Documents;

Table of Contents for the site-specific study start-up packet.

FUTURE PLANS



CONCLUSIONS

• The feedback from sponsors and CROs has been positive. Most state they are able to complete the majority of their site selection reports with the data provided in our site-specific study start-up packet prior to the PSSV.

HEALTH

• Time with the principal investigator and site study staff during the PSSV can now be spent more productively, addressing questions and discussing study-specific recruitment strategies and protocol requirements.

• Site selection timelines appear to have improved, especially in our Phase I experimental therapeutics space, where rapid site selection is necessary, primarily for participation in dose escalation.

• Internal reports from management as well as sponsors and their CROs have confirmed that providing the study start-up packet prior to the PSSV allows for transparency, which improves communication and the sponsor/site relationship overall.

• Create and implement sponsor/CRO surveys to confirm feedback received to date and measure satisfaction

Begin discussion with CROs/sponsors regarding creation of databases to capture site-specific study start-up requirements, activation timelines, technical capabilities, and answers to frequently asked questions • Continue to update the New Study Start-up Documents as clinical research requirements and site

specific processes evolve